69 - Advisory Committees & Public Hearings (S5E9)

Ever wonder how a new drug goes from like a scientist
lab to your medicine cabinet? It's a fascinating
journey for sure. Right. It's not magic. Definitely
not magic. There's so much that goes on behind
the scenes. Absolutely. A lot of steps. And today
we're taking a deep dive into two really crucial
parts of that process. Advisory committees and
public hearings. They're kind of like checks
and balances. Yeah, exactly. They're all about
ensuring that the medications we all end up using
are safe and effective. That's the goal, right?
Making sure the drugs that make it to market
actually do what they're supposed to and don't
cause more harm than good. So we're going to
look at how these committees made up of experts
and these opportunities for the public to weigh
in, how they actually play a part in those decisions
made by drug regulators like the FDA. We're talking
about transparency and how this all ultimately
impacts what drugs get approved and even like
how those drugs are labeled. And to really illustrate
how this works in the real world, we're going
to use a recent case. As an example, the story
of Lycos and their drug, midomefetamine. Yeah,
that's a perfect example to unpack how this all
plays out. So let's start with these advisory
committees. OK. Who are these people and what's
their primary job in this whole process? Well,
you can think of these committees as a group
of independent experts brought in for their specific
knowledge. So we're talking doctors, scientists,
statisticians. Exactly. People who really understand
the science behind. the drug being reviewed and
this independence is crucial. Why is that? Well,
it helps to safeguard against any potential bias,
you know, from the company that's actually developing
the drug. Makes sense. So it's a way to get a
more objective evaluation of all the data. Exactly.
Their main role is to provide impartial advice
and recommendations to the regulatory agencies
like the FDA. So they're basically advisors providing
a second opinion. Yeah, you could think of it
that way. And they're tackling the complex scientific
and medical questions that come up during the
review. So when does this expert team actually
get called in during the drug review process?
It's not like they're involved in every single
drug that comes along. It's typically when a
regulatory agency is facing a situation where
the data is particularly complex. So if there's
some debate about the results or maybe some concerns
about the safety. Exactly. Or maybe if how well
the drug works isn't entirely clear. So it's
like bringing in the big guns for the tough cases.
Yeah. And this usually happens after the company
has submitted their whole application for approval,
but before the agency makes their final decision.
So the drug company hands over this massive amount
of research, their trial results. everything
they've got. It's a lot of information to sift
through. And what exactly does the advisory committee
do with this mountain of data? They really dig
deep. They analyze everything the company has
provided, but they don't stop there. So they're
not just taking the company's word for it. No,
they also look at any other relevant information
that's out there. So they could be published
studies or even their own clinical insights from
their own experience. Exactly. And then the committee
gets together often in a public setting to discuss
the drug. So it's very transparent. Yes. And
they'll hear presentations from the company,
from the agency itself, and sometimes even from
patients and advocates. It's like a big meeting
of the minds to figure out what's going on with
this drug. Yeah. And it leads to some really
interesting discussions and debates. So it's
a weighing of the evidence, a back and forth
about the pros and cons. Precisely. They're focused
on the key questions. You know, is this drug
safe enough for the people it's intended for?
And does it actually work? Does the evidence
show that it's effective? Exactly. And this whole
process usually ends with a vote. So each member
of the committee gets to say, I think this drug
should be approved or I don't think it should
be approved. Yeah, it's like a collective expert
opinion that they give to the regulatory agency.
So that's got to be it. Right? If the experts
say no, the drug's basically dead in the water.
Not always, but it's definitely a major hurdle
to overcome. It's like getting a thumbs down
from the people who know the most about this
stuff. Yeah. And while the agency isn't legally
bound to follow the committee's recommendation,
they do take it very seriously. It's like getting
advice from your most trusted advisor. You're
probably going to listen to what they have to
say. And a negative vote from an advisory committee
carries a lot of weight. OK, so that's the expert
perspective. But we also mentioned public hearings.
Right. How do those fit into this whole picture?
Public hearings offer a different but equally
important kind of input. So we're shifting gears
a bit. Yeah, this is where patients who might
actually benefit from the drug, their families,
advocacy organizations, all these different voices,
get to share their perspectives. So it's less
about the hardcore scientific data and more about
the real world experience. of living with the
condition the drug is supposed to treat. Exactly.
Patients can talk about what it's like to live
with the illness, what their current treatment
options are like, if those options are working
for them or not. And what they hope this new
drug might do for them. Right. It's about highlighting
the unmet needs and sharing their thoughts on
the potential benefits and risks of the new drug.
It brings the human element into the decision
-making process. It's a crucial reminder that
these decisions affect real people's lives. a
much richer understanding of the situation. It
helps them to understand the potential real world
impact of their decision from the patient's perspective.
Because at the end of the day, it's the patients
who will be taking these drugs. And that's why
these hearings are so important for transparency
in the whole regulatory process. So let's talk
more about that transparency. OK. How do these
expert committees and public hearings make the
drug approval process more open and accountable?
Well, for one thing, as we mentioned, advisory
committee meetings are often open to the public.
Anyone can attend. So it's not some secret meeting
behind closed doors. No. And recordings of the
meetings are often made available afterwards,
too. So you can go back and listen to what was
discussed. Exactly. And all the documents that
the committee looks at, like the agenda, the
data, the meeting minutes, those are often publicly
accessible as well. It's like putting everything
out in the open so everyone can see what's going
on. Right. And public hearings by their very
nature are open forums for discussion. So anyone
can come and share their thoughts. Exactly. And
this openness is really important because it
allows researchers, journalists, patient groups,
anyone who's interested to really understand
how these decisions are being made. It's about
building trust in the system. And holding everyone
accountable. So we've talked about the experts
and we've talked about the public input, but
how do those actually influence the final decision
on whether a drug gets approved or not and what
its label will look like? It's a complex process
but ultimately the decision rests with the regulatory
agency. But the experts and the public do have
a say. Yes. Their input is a critical part of
the overall evaluation. So a strong positive
recommendation from the advisory committee makes
it much more likely that the drug will get approved.
Right. And on the flip side a negative recommendation
as we discussed can be a big obstacle. It's not
a guarantee but it definitely makes things more
difficult. And what about those public hearings?
Can a really compelling patient's story actually
sway the regulators? That's a good question.
While individual stories might not override strong
scientific evidence, the themes and concerns
that come up during a public hearing can definitely
influence the agency's thinking. Especially when
it comes to understanding the balance between
the risks and benefits of a drug from the patient's
perspective. Exactly. And it can also have a
direct impact on the drug's labeling. The information
that comes with the drug about how to use it
safely effectively. Right. The labeling might
include details about potential side effects
to watch out for or specific groups of patients
who should or shouldn't use the drug. So these
discussions can lead to a more comprehensive
and patient focused approach to labeling. It's
about making sure that the information about
the drug is clear and relevant to the people
who will be using it. OK, so we've laid out the
general process, but let's get back to our case
study Lycos and their drug, midelmephedamine.
Right. Let's see how this all played out in a
real world scenario. So what was the situation
with this drug? Well, modomafetamine was under
review for a specific medical condition. And
as part of that process, it went before an advisory
committee, just like we've been talking about.
And what happened at that meeting? The advisory
committee ultimately issued a negative recommendation.
So the majority of the experts voted against
approving the drug. Yes, that's correct. Wow.
That's a big setback, as we've discussed. So
what were the main reasons why they decided to
recommend against approval? Well, based on the
information that's publicly available and the
typical factors that are considered in these
kinds of decisions, the concerns usually revolve
around two key things, efficacy and safety. efficacy
meaning does the drug actually work and safety
meaning is it safe enough to use. Exactly. So
the committee would have carefully weighed all
the data that Lycos presented looking at whether
the evidence was strong enough to show that the
drug works for its intended purpose and whether
any potential risks or side effects outweighed
those benefits. So it's a balancing act trying
to figure out if the potential benefits outweigh
the potential risks. Absolutely. And some of
the specific concerns might have been things
like how strong and consistent the clinical trial
results were, how big of an effect the drug had,
and whether any red flags came up about potential
safety issues during those studies. So they're
really scrutinizing everything to make sure that
the drug is both effective and safe. That's the
goal. Was there a public hearing held for mid
-elmofetamine as well? It's actually quite common
for drugs that are meant to treat serious conditions,
especially ones where there aren't many good
treatment options already available. So if there's
a big unmet need for a drug like this, they want
to hear from the patients who might benefit from
it. Exactly. And that would have given patients
and advocacy groups a chance to share their perspectives
specifically on midomafetamine. So we have the
expert committee recommending against approval
and potentially the public weighing in as well.
What did the regulatory agency ultimately decide?
In the case of midomefetamine, the agency decided
to follow the advisory committee's recommendation.
So they didn't approve the drug for its intended
use at that time? That's correct. It really shows
how much weight these advisory committees can
have in the final decision. Yes. They play a
crucial role in the process. It's a complicated
system, but it seems like there are a lot of
safeguards in place to make sure that drugs are
thoroughly vetted. before they become available
to patients. It's about finding the right balance
between being cautious and being innovative.
Making sure that new treatments are both safe
and effective. And that's not always an easy
task. So to sum up our deep dive today, advisory
committees made up of independent experts and
public hearings where patients and advocates
can have their voices heard. are both incredibly
important parts of the drug approval process.
They add layers of scrutiny and transparency
to the decisions that are being made. And they
can have a major impact on the final outcome,
as we saw with Lycos and mitoamphetamine. They're
not just rubber stamps. They're actively involved
in shaping the future of medicine. It makes you
think about the whole process in a different
light, doesn't it? It definitely highlights the
complexity of bringing new drugs to market. There's
the rigorous scientific evaluation. But then
there's also the human side of it, the experiences
of the patients who are waiting for new treatments.
It's about finding a balance between those different
perspectives. And the regulatory agencies have
the tough job of trying to weigh all of that
information and make the best decision for the
public's health. It's a lot of responsibility.
It really is. And it raises some interesting
questions for all of us to think about. Like
how much weight should be given to the opinions
of experts versus the needs of patients? And
how can we ensure that the drug approval process
is as transparent and accountable as possible?
These are questions that we all need to be thinking
about as new drugs and new technologies continue
to emerge. Absolutely. So we encourage you to
keep learning about this if you're interested.
Yeah. Go check out the information about specific
advisory committee meetings. It's all publicly
available. The agendas, the discussions, even
the voting records. You can see how the decisions
are made. And take a look at the regulations
that govern drug approval. It's all out there
if you want to learn more. It's a fascinating
glimpse into the behind the scenes world of drug
development. It really is. Thanks for joining
us for this deep dive. It was great to be here.
And we'll see you next time. Sounds good.